Tzu J, Krulig E, Cardenas V, Kerdel F A
Department of Dermatology and Cutaneous Surgery, Leonard Miller School of Medicine at the University of Miami, Miami, FL, USA.
G Ital Dermatol Venereol. 2008 Oct;143(5):315-27.
Psoriasis is a chronic immune-mediated inflammatory disease, with an estimated prevalence of 1-3% worldwide. It is considered to be a multisystemic disorder, primarily affecting the skin and joints (psoriatic arthritis), and associated with other inflammatory conditions such as inflammatory bowel disease and coronary heart disease among others. Today, thanks to recent scientific advances that have allowed us to deepen our understanding of the pathogenesis of psoriasis, we count with an expanded therapeutic armamentarium that includes targeted therapy in the form of ''biologics''. These agents have gained popularity as safe, effective, and convenient alternatives for the treatment of chronic moderate to severe plaque psoriasis. This review will focus on the main biologics used in the treatment of moderate to severe plaque psoriasis: efalizumab, alefacept, etanercept, infliximab, adalimumab and the new Interleukin (IL) 12/23 inhibitors.
银屑病是一种慢性免疫介导的炎症性疾病，全球估计患病率为1%-3%。它被认为是一种多系统疾病，主要影响皮肤和关节（银屑病关节炎），并与其他炎症性疾病如炎症性肠病和冠心病等相关。如今，由于最近的科学进展使我们能够更深入地了解银屑病的发病机制，我们拥有了更广泛的治疗手段，其中包括以“生物制剂”形式的靶向治疗。这些药物作为治疗慢性中度至重度斑块状银屑病的安全、有效且方便的替代药物而受到欢迎。本综述将聚焦于用于治疗中度至重度斑块状银屑病的主要生物制剂：依法利珠单抗、阿法赛特、依那西普、英夫利昔单抗、阿达木单抗以及新型白细胞介素（IL）12/23抑制剂。
